Close Menu

Biocept

NEW YORK (GenomeWeb News) – Oncology diagnostics company Biocept said on Friday that its revenues for 2013 increased 23 percent year over year.

NEW YORK (GenomeWeb News) – Biocept said after the close of the market on Monday that it has closed its initial public offering, raising $19 million in gross proceeds.

NEW YORK (GenomeWeb News) – Biocept today went public as shares of its common stock began trading at $10, the low end of an anticipated price range on its initial public offering.

Becton Dickinson disclosed during its fiscal fourth quarter and full-year earnings call several changes to its executive leadership.

NEW YORK (GenomeWeb News) – Biocept today set the price range on its planned initial public offering, saying it expects to price its shares between $10 and $12.

NEW YORK (GenomeWeb News) – Circulating tumor cell-based diagnostics firm Biocept on Monday filed with US regulators to go public with an initial public offering intended to raise up to $24.25 million.

Biocept Laboratories, a San Diego-based oncology laboratory specializing in circulating tumor cells and biomarker analysis, has developed a pair of PCR-based assay technologies that it claims can identify and quantify single mutations in a background of between 10,000 and 100,000

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – GE Healthcare's Clarient will commercialize Biocept's blood test for circulating tumor cells under a deal announced today.

Movers & Shakers: May 6, 2011

Premium

Lyle Arnold, Michael Dunn, Gilbert Omenn, Matthew Potter, David Bartel, Arthur Beaudet, George Church

People in the News: May 5, 2011

Premium

Lyle Arnold, Michael Dunn join Biocept management team; HTG appoints John Lubniewski as chief business officer; Ora Hirsch Pescovitz joins Life Tech's board

Pages

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.